Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CYP46A1 | Q9Y6A2 | 4/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18869482 | 1.00 | GLI1 (0.36) | GLI1EPHX2CYP2D6BCHEDPP4 | |
| SCHEMBL24511671 | 1.00 | GLI1 (0.36) | GLI1EPHX2CYP2D6BCHEDPP4 | |
| SCHEMBL197080 | 0.89 | — | — | |
| SCHEMBL21545609 | 0.89 | GLI1 (0.41) | GLI1CYP2D6BCHEDPP4MME | |
| SCHEMBL2950685 | 0.80 | LMNA (0.43) | GLI1BCHEDPP4MMEHTT | |
| SCHEMBL2950683 | 0.80 | LMNA (0.43) | GLI1BCHEDPP4MMEHTT | |
| SCHEMBL8181948 | 0.80 | GLI1 (0.36) | GLI1CYP2D6BCHEDPP4MME | |
| SCHEMBL13783333 | 0.80 | GLI1 (0.36) | GLI1CYP2D6BCHEDPP4MME | |
| SCHEMBL12437074 | 0.80 | GLI1 (0.36) | GLI1CYP2D6BCHEDPP4MME | |
| SCHEMBL14492218 | 0.80 | GLI1 (0.36) | GLI1CYP2D6BCHEDPP4MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092069-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2026-04-02 | — | — | US | disclosed |
| US-12448385-B2 | Substituted indazoles as IRAK4 inhibitors | ASTRAZENECA AB (SE) | 2025-10-21 | — | — | US | disclosed |
| US-20240182479-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-06 | — | — | US | disclosed |
| US-11866405-B2 | Substituted indazoles as IRAK4 inhibitors | ASTRAZENECA AB (SE) | 2024-01-09 | — | — | US | disclosed |
| EP-4259632-A1 | N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA | Astrazeneca AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022122876-A1 | N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| US-20220185817-A1 | IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | US | disclosed |
| US-20220185817-A1 | IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | US | disclosed |
| WO-2022122876-A1 | N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
| WO-2014090147-A1 | PYRIMIDINE DERIVATIVES AND SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2014-06-19 | — | — | WO | disclosed |
| US-5411989-A | Cardiovascular disorders | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092069-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | IRAK3, IRAK4, IRAK2 | GLI1 3411/4885EPHX2 3333/4885CYP2D6 2032/4885 |
| US-12448385-B2 | Substituted indazoles as IRAK4 inhibitors | IRAK4, IRAK1, IRAK2 | GLI1 3178/4885EPHX2 4315/4885CYP2D6 2512/4885 |
| US-11866405-B2 | Substituted indazoles as IRAK4 inhibitors | IRAK4, IRAK1, IRAK3 | GLI1 3076/4885EPHX2 4440/4885CYP2D6 3188/4885 |
| US-20240182479-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK2 | GLI1 2575/4885EPHX2 4351/4885CYP2D6 2964/4885 |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, PIK3R5, PIK3R2 | GLI1 1286/4885EPHX2 4374/4885CYP2D6 1628/4885 |
| US-20220185817-A1 | IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | GLI1 3062/4885EPHX2 4163/4885CYP2D6 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.